Mark Collar has joined Triathlon Medical Ventures as a venture partner. He had retired last year as president of Procter & Gamble's global pharma and personal health division.
Triathlon Medical Ventures Inc., a Midwest-based venture capital firm that invests exclusively in the life sciences, today announced that Mark Collar has joined the group as a venture partner. Collar, who retired last year as president of Procter & Gamble's Global Pharmaceuticals and Personal Health division, brings 15 years of pharmaceutical expertise, relationships and market insight to Triathlon.
“We are extremely pleased to have Mark join us at Triathlon,” said John Rice, co-founder and a managing partner at Triathlon. “His broad-spectrum knowledge of the pharmaceutical business — from discovery and development through launch and sales — strengthens the diversity of our existing expertise in medical devices and biotechnology.”
Rice continued, “Mark brings strategic thinking, analytical ability and a realm of new relationships that we can call upon for the benefit of our fund and our portfolio companies. Having Mark on board gives us more capacity to look at more deals. This is great news for our management team and great news for Triathlon's investors.”
Collar, 55, began his career at Procter & Gamble in 1975 as a sales representative, and progressed through a number of divisions with increasing responsibility. He moved to the Pharmaceuticals division in 1994, becoming president of Global Pharmaceuticals in 2002 and assuming the additional responsibility for the Global Personal Health business in 2005.
Highly regarded for his industry expertise, Collar serves on a number of national, regional, state and local boards. He was recently named to the board of directors of Ohio-based AtriCure, Inc, a publicly traded medical device company. He was appointed by the governor and currently is chairman of the Third Frontier Advisory Board, which provides direction for
About Triathlon Medical Ventures Inc.
Triathlon Medical Ventures provides equity capital to early- and expansion-stage companies with proprietary biomedical technology platforms or products addressing significant human healthcare needs. The firm is geographically focused on early-stage opportunities in the